We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Asu5.5
ASU Research
Too few graded studies
24 peer-reviewed studies
What the evidence says
Too few graded studies
ASU doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 1997–2025 with a typical study size of 5,980 participants.
Based on 24 studies · 6 meta-analyses · 10 RCTs · 5,980 total participants
Confidence
High confidence
What the studies found
1helped· 23 more without graded effect data
By outcome
Joint pain & arthritisReduces knee osteoarthritis pain and improves function (not hip OA) · 1-3 months
Too few graded studies23 studies
Safety profile
Too few graded studies2 studies
InflammationReduces hip and knee osteoarthritis pain in meta-analyses of RCTs, inflammatory markers not established · 1-3 months
Too few graded studies1 study
Steady research
6 studies in the last 5 years · Latest meta-analysis: 2019
199720112025
1Physical function (WOMAC)Meta-AnalysisCited 80×n=5,980 · very large study2014
In plain English: Evidence for the proprietary ASU product Piasclidine® in the treatment of osteoarthritis symptoms seems moderate to high for short term use, but studies over a longer term and against an apparently active control are less convincing.
Cameron M et al. · The Cochrane database of systematic reviews (2014)
Noticeable benefit
← WorseNo effectBetter →
Seventeen studies of confirmatory design (sample and effect sizes pre-specified) were mostly at moderate risk of bias.
Physical function was 33 points on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 0 to 100 point subscale (0 is no loss of function) with placebo, enriched Boswellia serrata improved function by 8 points (95% CI 2 to 14); NNTB 4.
Moderate-quality evidence (one study, 96 participants) indicated that adverse events were probably reduced with enriched Boswellia serrata (18/48 events versus 30/48 events with placebo; relative risk (RR) 0.60, 95% CI 0.39 to 0.92).
In plain English: Despite some discrepancies regarding structural changes in the joints, clinical trials typically demonstrate symptom relief and slow down the disease progression.
Sabucedo-Suárez A, López-Peña M, Permuy M, Muñóz F. · Frontiers in veterinary science (2024)
Although results vary, pre-clinical research in different animal models has demonstrated positive effects, such as ameliorating histopathological changes and reduced inflammation.
Despite some discrepancies regarding structural changes in the joints, clinical trials typically demonstrate symptom relief and slow down the disease progression.
While ASU demonstrates significant promise in alleviating OA symptoms and reducing reliance on NSAIDs, further research is essential to fully understand its mechanisms of action.